Next Article in Journal
Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson’s Disease Models
Previous Article in Journal
Molecular Tools for the Detection and the Identification of Hymenoptera Parasitoids in Tortricid Fruit Pests
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessCase Report
Int. J. Mol. Sci. 2017, 18(10), 2038; doi:10.3390/ijms18102038

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom’s Macroglobulinemia

1
Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA, Nedlands 6009, Australia
2
Department of Anatomical Pathology, Pathwest Laboratory Medicine WA, Nedlands 6009, Australia
3
Medical School, University of Western Australia, Crawley 6009, Australia
*
Author to whom correspondence should be addressed.
Received: 30 August 2017 / Revised: 19 September 2017 / Accepted: 20 September 2017 / Published: 22 September 2017
View Full-Text   |   Download PDF [1372 KB, uploaded 22 September 2017]   |  

Abstract

The application of molecular genomics and our understanding of its clinical implications in the diagnosis, prognostication and treatment of lymphoproliferative disorders has rapidly evolved over the past few years. Of particular importance are indolent B-cell malignancies where tumour cell survival and proliferation are commonly driven by mutations involving the B-cell receptor and downstream signalling pathways. In addition, the increasing number of novel therapies and targeted agents have provided clinicians with new therapeutic options with the aim of exploiting such mutations. In this case report, we highlight one such success story involving the diagnostic impact of the MYD88L265P mutation in Waldenstrom’s macroglobulinemia (WM), its prognostic implications and effect on choice of therapy in the era of novel therapies. View Full-Text
Keywords: Waldenstrom’s macroglobulinemia; MYD88; Bruton’s tyrosine kinase (BTK) inhibitors; molecular diagnostics Waldenstrom’s macroglobulinemia; MYD88; Bruton’s tyrosine kinase (BTK) inhibitors; molecular diagnostics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chin, C.K.; Leslie, C.; Grove, C.S.; Van Vliet, C.; Cheah, C.Y. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom’s Macroglobulinemia. Int. J. Mol. Sci. 2017, 18, 2038.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top